Proprietary portfolio

We develop superior therapeutics that are clinically derisked and address unmet patient need in high value markets including diabetes and other cardiometabolic diseases, based on our Arestat® technology platform

OUR PORTFOLIO

Partnering

We partner with leading pharmaceutical and medtech companies to develop superior therapeutic profiles, leveraging our innovative and proprietary formulation and drug delivery technology

PARTNERING

Validated technology

Our development expertise is underpinned by our world-leading Arestat® technology platform, protected by a robust intellectual property portfolio

OUR TECHNOLOGY

Latest News

  • 30th September 2026

    Interim results for the six months to 30 June 2026

    CLICK HERE
  • 30th September 2026

    Proposed Fundraising to raise up to £5.13 million

    CLICK HERE
  • 17th August 2026

    HCP Live: Investigational Rapid-Acting U500 Insulin Maintains Efficacy Regardless of BMI

    CLICK HERE